- Home
- HL vs LNTH Comparison
HL vs LNTH Comparison
Compare HL & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HL
- LNTH
- Stock Information
- Founded
- HL 1891
- LNTH 1956
- Country
- HL United States
- LNTH United States
- Employees
- HL N/A
- LNTH N/A
- Industry
- HL Precious Metals
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HL Basic Materials
- LNTH Health Care
- Exchange
- HL Nasdaq
- LNTH Nasdaq
- Market Cap
- HL 3.9B
- LNTH 3.6B
- IPO Year
- HL N/A
- LNTH 2015
- Fundamental
- Price
- HL $7.69
- LNTH $54.05
- Analyst Decision
- HL Hold
- LNTH Strong Buy
- Analyst Count
- HL 5
- LNTH 6
- Target Price
- HL $7.60
- LNTH $105.50
- AVG Volume (30 Days)
- HL 21.4M
- LNTH 2.1M
- Earning Date
- HL 08-06-2025
- LNTH 08-06-2025
- Dividend Yield
- HL 0.20%
- LNTH N/A
- EPS Growth
- HL N/A
- LNTH N/A
- EPS
- HL 0.16
- LNTH 3.77
- Revenue
- HL $1,060,106,000.00
- LNTH $1,520,653,000.00
- Revenue This Year
- HL $13.45
- LNTH $4.57
- Revenue Next Year
- HL $3.13
- LNTH $9.41
- P/E Ratio
- HL $48.37
- LNTH $14.44
- Revenue Growth
- HL 36.30
- LNTH 5.75
- 52 Week Low
- HL $4.46
- LNTH $47.25
- 52 Week High
- HL $7.85
- LNTH $118.21
- Technical
- Relative Strength Index (RSI)
- HL 71.13
- LNTH 29.17
- Support Level
- HL $5.62
- LNTH $51.40
- Resistance Level
- HL $7.87
- LNTH $57.21
- Average True Range (ATR)
- HL 0.26
- LNTH 2.21
- MACD
- HL 0.15
- LNTH -1.03
- Stochastic Oscillator
- HL 87.75
- LNTH 27.75
About HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.